not used title
not used title
You may have heard in the news about the growing public health threat of antimicrobial resistance — often referred to as AMR. AMR is a natural process that occurs when harmful microorganisms like bacteria, viruses, fungi and parasites develop the ability to survive against drugs designed to kill them. This resilience can make common infections harder to treat and can lead to severe health complications, longer hospital stays and even death — in fact, AMR accounts for nearly five million deaths globally each year. As AMR continues to escalate, it poses a significant global threat, rendering previously treatable diseases more dangerous and costly to manage.
Unfortunately, the pipeline for developing new antibiotics has significantly dwindled over the years due to misaligned incentives that plague the market. The process of researching and developing a new antimicrobial medicine is lengthy, typically spanning from 10 to 20 years, with only one out of every 15 products managing to gain approval from the U.S. Food and Drug Administration (FDA) and ultimately reach patients. Even upon receiving approval, the implementation of stewardship programs designed to slow resistance and ensure novel antimicrobials are used appropriately can make it challenging for companies to earn sufficient revenues to recoup the investment needed to bring new antimicrobials and antifungals to patients.
In the battle against what the World Health Organization considers to be “one of the biggest threats to global health, food security and development today,” the PASTEUR Act has emerged as a beacon of hope. Enacted to tackle the rising threat of AMR, this bipartisan legislation has garnered widespread support from scientists, health care providers and policymakers alike. Under the PASTEUR Act, the government would offer "subscription contracts" to manufacturers for novel antimicrobial drugs, establishing a guaranteed market for these medicines upon their approval by the FDA. The primary goal of this policy is to incentivize companies to develop antimicrobial medicines for infections in which there is unmet medical need, anticipated clinical need or drug resistance.
AMR is a complex issue that demands immediate attention and action. By ensuring appropriate use of antibiotics, establishing a guaranteed market for novel antimicrobial products and fostering global cooperation, we can hope to slow down and eventually reverse the rise of antimicrobial resistance. The time to act is now before AMR becomes an even more formidable adversary than it already is.
Learn more about the growing threat of AMR.
Jocelyn Ulrich
Jocelyn Ulrich, MPH, is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.
Jocelyn Ulrich
Bayh-Dole: The fuel for America’s innovation engine
September 2, 2026
ICYMI: Biopharmaceutical companies in America hit new investment milestone
August 14, 2026
World Sickle Cell Day: Recognizing the promise of gene therapy
June 19, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
How AI is transforming the drug innovation lifecycle
March 19, 2026
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
PhRMA Foundation celebrates 60 years of investing in future scientific leaders
June 11, 2025
New report: Post-approval innovation delivers substantial patient benefits
June 2, 2025
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
4 things to know on Rare Disease Day
February 28, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
Reimagining patient access through meaningful policy reform
November 5, 2024
Leveraging the power of vaccines to prevent antimicrobial resistance
October 31, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
Addressing the mounting threat of antimicrobial resistance
September 23, 2024
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
September 19, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
How to protect your children’s health this school year
August 22, 2024
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
August 1, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
Women’s Health Month: A conversation with Astellas
May 31, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
Women’s Health Month: A conversation with Sage
May 23, 2024
The use of real-world data in drug development
May 13, 2024
New analysis: Accelerated approval pathway is changing lives in underserved communities
April 30, 2024
ICYMI: Voter priorities this election season
April 18, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
What new cures would mean to families
March 7, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
Proposed march-in framework would chill American innovation
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
January 25, 2024
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
January 23, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The White House continues to attack American innovation
December 15, 2023
Taking stock of obesity and its costly effects
December 8, 2023
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
Misuse of march-in could stifle innovation
November 27, 2023
A conversation with Sepsis Alliance President and CEO Thomas Heymann as World AMR Awareness Week kicks off
November 21, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
Don't close the door on rare disease research
November 13, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
Word of the Month: The Bayh-Dole Act
November 8, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
Celebrating Hispanic Heritage Month at PhRMA
October 11, 2023
New analysis shows PBMs use fees as a profit center
September 18, 2023
New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients
September 11, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
Decentralized clinical trials and the future of drug development
August 9, 2023
WTAS on reasonable pricing and public-private partnerships
August 8, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
A conversation with Dr. Mike Ybarra on the current state of COVID-19
June 27, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
Biopharmaceutical science powered by PRIDE
June 16, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Reject efforts to undermine America’s R&D ecosystem
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
4 key facts on medicine prices and spending
May 9, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
New resource underscores the importance of small molecule medicines
May 4, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
Policies need to address the growing threat of antimicrobial resistance
April 28, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
New global analysis shows patient access challenges around the world
April 12, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
Celebrating 40 years of the Orphan Drug Act on Rare Disease Day
February 28, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
What they are saying: PASTEUR Act can help fight antimicrobial resistance
November 30, 2022
Word of the Month: What is TRIPS?
November 29, 2022
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
November 17, 2022
Congratulations to our 2022 Working for Cures Employee Champions
November 10, 2022
New government price setting policy threatens post-approval research
November 10, 2022
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
November 8, 2022
New paper: Addressing the growing crisis of mental health and substance use disorders
November 7, 2022
Protecting treatment advances for breast cancer
October 31, 2022
The law driving technology transfer and fostering innovation
October 24, 2022
Word of the Month: Long COVID
October 19, 2022
Don’t take anti-innovation, activist funded academics at their word
October 18, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
New Report: Nearly 800 medicines in development to treat chronic conditions
September 29, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
Recognizing National Sickle Cell Awareness Month
September 23, 2022
Word of the Month: 340B covered entity
August 29, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
New survey: Voters seriously concerned about fine print in reconciliation bill
August 12, 2022
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
August 10, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
An open letter to Congress: Stand with patients and future cures
August 4, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
August 1, 2022
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
July 29, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: American medical innovation
July 27, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
The Patient Perspective: Government price-setting harms patients
July 22, 2022
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
July 18, 2022
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
July 14, 2022
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
July 14, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
Word of the Month: Biomarkers and surrogate endpoints
July 11, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
July 6, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
Key takeaways from ASCO's annual meeting
June 10, 2022
Biopharmaceutical researchers to discuss the value of R&D with Congress
June 9, 2022
Recognizing LGBTQ+ Pride in biopharmaceutical science
June 9, 2022
Report: More than 500 medicines in development to treat disorders of the blood
May 18, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
Ensuring timely reauthorization of PDUFA and BsUFA
May 11, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
Spotlighting a growing mental health challenge
May 9, 2022
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
April 28, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
The biopharmaceutical industry leads in helping women achieve new heights, according to IAM’s diversity 100
April 20, 2022
Report: More than 600 medicines in development for diseases affecting women
March 31, 2022
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
March 17, 2022
Biopharmaceutical industry drives economic growth in all 50 states
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
Biopharmaceutical research and development has ushered in a decade of innovation in rare disease
February 28, 2022
4 things to know about biopharmaceutical efforts to fight cancer
February 24, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
The importance of timely PDUFA and BsUFA reauthorization
February 3, 2022
Medicaid 101: Three charts on access and spending
February 3, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
Protecting U.S. innovation abroad to support economic and pandemic recovery
February 1, 2022
New comments outline ways to counteract cost-shifting insurance trends
January 28, 2022
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
January 26, 2022
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
January 24, 2022
New data show continued decline in death rates for cancer patients related to treatment advances
January 20, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
Making medicines more affordable: Preserving safety-net programs like 340B
December 17, 2021
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
New Report: Nearly 800 new medicines in development to treat rare diseases
December 16, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021